Sub-Sensitivity to Long-Acting Bronchodilators (LABA)
| 対象疾患 | Asthma |
|---|---|
| 相 | 該当なし |
| スポンサー | National Jewish Health |
| ステータス | 完了 |
| 参加者数 | 20 名 |
| 介入（薬剤） | fluticasone propionate and salmeterol, budesonide and formoterol |
| 開始日 | 2010年3月 |
| 完了日 | 2013年9月 |
| 結果公開日 | 2026年7月6日 |
概要
The purpose of this study is to look at whether Advair® and SYMBICORT® have different effects on airway constriction by means of methacholine challenge testing.
Improvement in PC20
| Fluticasone Propionate and Salmeterol | 0.55 PC20 mg/ml |
|---|---|
| Budesonide and Formoterol | 0.41 PC20 mg/ml |
| Fluticasone Propionate and Salmeterol | 0.64 PC20 mg/ml |
| Budesonide and Formoterol | 0.47 PC20 mg/ml |
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- A Study of Remote Asthma Management Using an Integrated Artificial Intelligence-assisted E — Mayo Clinic
- Developing a Childhood Asthma Risk Passive Digital Marker — Indiana University
- A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With C — Chiesi Farmaceutici S.p.A.
- A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to — Hoffmann-La Roche
- A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Cortic — Hoffmann-La Roche
- Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Sev — AstraZeneca